YOLFTbeta
Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc.

TECX · NASDAQ · Healthcare / Biotechnology

21.14USD+0.10 (+0.48%)

Price History

Full chart

Market Stats

Previous Close21.04
Open20.96
Day Range20.11 – 21.29
52-Week Range14.60 – 39.53
Volume300.64K
Market Cap459.61M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.53
Dividend Yield0.00%
Beta0.22
50-Day Avg30.92
200-Day Avg27.91

About

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Alise S. Reicin M.D., Ph.D.
  • Employees60
  • Headquarters490 Arsenal Way, Watertown, MA, United States, 02472, USA
  • Websitehttps://tectonictx.com

Leadership

  • Dr. Alise S. Reicin M.D., Ph.D.President, CEO, Secretary & Director · b. 1961
  • Mr. Daniel Lochner M.B.A.Chief Financial Officer · b. 1982
  • Dr. Marcella Kuhlman Ruddy M.D., M.S.Chief Medical Officer · b. 1963
  • Mr. Washington Alves M.S.Senior Vice President of Technical Operations
  • Dr. Peter McNamara Ph.D.Chief Scientific Officer · b. 1972
  • Ms. Geraldine Peters-WilesSenior Vice President of Human Resources
  • Mr. Anthony Muslin M.D.Chief Development Officer
  • Dr. Marc Schwabish Ph.D.Chief Business Officer · b. 1980
  • John DienerSenior Vice President of Antibody Engineering & Protein Sciences

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----00000
Cost of Revenue-45.00K380.00K850.00K1.21M1.40M4.17M617.00K1.65M-
Gross Profit--45.00K-380.00K-850.00K-1.21M-1.40M-4.17M-617.00K-1.65M-
Operating Expense-18.34M45.86M74.96M119.02M14.21M28.66M44.03M56.37M-
Operating Income-4.63M-18.39M-46.24M-75.81M-120.23M-15.61M-32.83M-44.65M-58.02M-84.04M
EBITDA-4.66M-18.60M-45.98M-72.11M-118.50M-8.12M-31.03M-41.19M-56.23M-71.48M
Net Income-4.66M-18.65M-46.36M-72.97M-119.71M-8.93M-32.18M-42.82M-57.98M-74.15M
R&D2.66M15.19M35.09M54.97M86.03M10.98M25.65M36.97M41.36M63.49M
Interest Expense-----224.00K144.00K152.00K107.00K63.00K

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets5.40M7.02M133.48M200.51M271.23M32.88M47.21M39.40M152.91M261.04M
Total Liabilities979.00K3.66M11.29M14.50M16.89M47.84M92.86M124.03M12.13M9.71M
Total Equity4.42M3.37M122.18M186.01M254.34M-14.96M-45.65M-84.64M140.78M251.33M
Cash5.36M5.96M126.30M187.04M259.68M28.06M35.97M28.77M141.24M253.80M
Total Debt-----1.05M5.79M4.34M3.30M1.28M
Net Debt-5.36M-5.96M-126.30M-187.04M-259.68M-27.01M-30.17M-24.43M-137.94M-252.52M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.31M-16.38M-37.65M-67.67M-98.80M-12.45M-97.21M-40.68M-59.08M-60.08M
Investing Cash Flow-24.00K-383.00K-1.83M-1.58M-1.18M-2.12M-267.00K-279.00K-156.00K-138.00K
Financing Cash Flow8.70M17.37M160.29M129.99M172.62M41.42M262.00K33.75M171.71M173.35M
Capital Expenditure0383.00K1.83M1.58M1.18M2.12M267.00K279.00K156.00K208.00K
Free Cash Flow-3.31M-16.77M-39.48M-69.25M-99.98M-14.58M-97.47M-40.96M-59.24M-60.29M
FCF to OCF100.00%102.34%104.87%102.34%101.19%117.04%100.27%100.69%100.26%100.35%

Earnings

Report DateAug 9, 2018Nov 13, 2018Mar 25, 2019May 13, 2019Aug 8, 2019Nov 7, 2019Mar 16, 2020May 7, 2020Aug 6, 2020Nov 5, 2020Mar 18, 2021May 13, 2021Aug 5, 2021Nov 4, 2021Mar 17, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 23, 2023May 11, 2023Aug 10, 2023Nov 9, 2023Mar 20, 2024May 9, 2024Aug 14, 2024Nov 7, 2024Mar 12, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Feb 26, 2026May 7, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate-----0.75-0.59-0.59-0.66-0.76-0.80-0.89-0.75-0.66-0.76-0.74-0.58-0.57-0.55-0.49-0.55-0.54-0.35-0.43-0.36-1.30-0.84-1.39-1.09-0.98-1.05-1.11-1.17-1.41-1.38
EPS Actual-5.32-5.86-8.08-8.59-0.67-0.57-0.72-0.77-0.80-1.01-0.73-0.65-0.74-0.75-0.65-0.68-0.64-0.52-0.57-0.571.52-0.48-0.50-1.80-4.34-1.20-0.84-0.93-1.07-1.02-1.03-1.34-1.18-
Surprise----10.67%3.39%-22.03%-16.67%-5.26%-26.71%17.75%13.77%-11.78%1.04%12.10%-16.88%-11.85%5.45%-15.64%-3.64%381.01%-35.21%-16.28%-400.00%-233.85%-42.86%39.68%14.68%-9.18%2.86%7.21%-14.53%16.31%-
Timing------------------------After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap459.61M
Enterprise Value265.48M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.18
EPS-4.53
Book Value11.64
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-93.66M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-33.80%
Return on Assets-22.29%
Shares Outstanding19.55M
Shares Float11.91M
Beta0.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 6 analystsTarget 76.63
  • Strong Buy
    5
  • Buy
    1

Ownership Breakdown

Institutions
71.75%
Insiders
37.85%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    2.82M14.41%
  • TCG Crossover Management, LLC
    1.20M6.16%
  • Aberdeen Group PLC
    1.14M5.84%
  • BlackRock Inc
    860.35K4.40%
  • BRAIDWELL LP
    847.15K4.33%
  • First Light Asset Management, LLC
    800.73K4.10%
  • Baker Bros Advisors LP
    607.79K3.11%
  • 5AM Venture Management, LLC
    606.66K3.10%
  • Vanguard Capital Management, LLC
    473.53K2.42%
  • Vestal Point Capital LP
    328.00K1.68%
  • Bollard Group LLC
    302.95K1.55%
  • Kennedy Capital Management Inc
    282.20K1.44%
  • Geode Capital Management, LLC
    268.27K1.37%
  • Marshall Wace Asset Management Ltd
    229.59K1.17%

Top Fund Holders

  • Fidelity Growth Company Fund
    719.35K3.68%
  • Fidelity Select Biotechnology
    405.39K2.07%
  • Vanguard MStar Total Stk Mkt Idx Invest
    364.41K1.86%
  • iShares Russell 2000 ETF
    264.88K1.35%
  • abrdn Healthcare Investors
    260.43K1.33%
  • Fidelity Growth Company K6
    249.63K1.28%

Stock Splits

  • Jun 21, 20241:12